BLTE - 3 Soaring Biotech Stocks That Could Climb Much Higher
Whether you're new to investing or have been doing it for a very long time, the vast majority of the stocks in your portfolio are probably in the red this year. Rising interest rates are pushing growth stocks out of favor -- but not all of them.
This year, shares of the following three biotech stocks have soared in the opposite direction of the overall market. Moreover, Wall Street analysts think they could climb a lot higher.
Belite Bio (NASDAQ: BLTE) stock is up by about 179% this year in response to progress for its lead candidate. The clinical-stage biotechnology company is developing an experimental retinol-binding protein antagonist called LBS-008.
For further details see:
3 Soaring Biotech Stocks That Could Climb Much Higher